We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
OSI Pharmaceuticals announced that it has completed a stock-for-stock exchange
resulting in the acquisition of all minority interest shares of the company's
majority-owned UK-based diabetes and obesity subsidiary, Prosidion Limited.
ProteinOne moved into 9,000 square feet of lab and office space in Bethesda,
Md., after spending the past few years at the Technology Advancement Program
(TAP) at the University of Maryland in College Park.
Access Pharmaceuticals announced that it has executed an exclusive license agreement
granting Discus Dental, Inc. the U.S. marketing rights for amlexanox.
Inyx, Inc., a specialty pharmaceutical company with
a focus on niche drug delivery technologies and products, announced that it
has received from Kos Pharmaceuticals, Inc. a 10-year contractual relationship
to produce Kos' Azmacort Inhalation Aerosol product line.
Clinical trials professionals hope the FDA will have a new adverse event reporting
system (AERS) in place before the end of next year to help streamline the reporting
process, which has become increasingly onerous for researchers.
Barr Pharmaceuticals has agreed to drop a lawsuit against the FDA after receiving
confirmation from the agency that the company's generic version of sanofi-aventis'
Allegra-D will be eligible for 180 days of marketing exclusivity.
Syntarga BV announced that it has realized a first round of financing. Allocation
of funds will be towards the development of novel linker technologies for oncology
products and the establishment of partnerships with biotechnology and pharmaceutical
companies.